Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction‐associated steatotic liver disease: A multicentre study
Authors' conclusion
Imeglimin efficaciously improved liver inflammation and fibrosis in patients with T2D and MASLD, with no significant changes in liver fat content or stiffness. These findings suggest that imeglimin is a promising therapeutic drug for the management of MASLD in the context of T2D, warranting further research on its long-term efficacy and mechanisms of action.
Study context
- Population
- Patients with T2D complicated by MASLD
- Participants
- 80 patients
- Comparison
- Imeglimin vs no imeglimin for 24 weeks
- Outcome
- Improvement in liver function and fibrosis
- Follow-up
- 24 weeks
Main finding
As reported in the abstract
Liver function and fibrosis
- Significant reduction in AST, ALT and γ-GTP with imeglimin vs control
- Fib-4 index and FibroScan-AST (FAST) score significantly lower with imeglimin
Further findings
Glycaemic parameters · 24 weeks
- Significant reduction in HbA1c and fasting blood glucose with imeglimin vs control
Liver fat content and stiffness (FibroScan) · 24 weeks
- Liver fat content and stiffness remained unchanged
Original publication
Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction‐associated steatotic liver disease: A multicentre study. Diabetes Obes Metab. Published 26 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →